{
    "clinical_study": {
        "@rank": "149666", 
        "acronym": "DI-Leu16-IL2", 
        "arm_group": [
            {
                "arm_group_label": "0.5 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "0.5 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }, 
            {
                "arm_group_label": "1.0 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "1.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }, 
            {
                "arm_group_label": "2.0 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "2.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }, 
            {
                "arm_group_label": "4.0 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "4.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }, 
            {
                "arm_group_label": "6.0 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "6.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }, 
            {
                "arm_group_label": "8.0 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "8.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }, 
            {
                "arm_group_label": "10.0 mg/m2 DI-Leu16-IL2", 
                "arm_group_type": "Experimental", 
                "description": "10.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study."
            }
        ], 
        "brief_summary": {
            "textblock": "An open-label, dose-escalation trial of the safety, tolerability, pharmacokinetics (PK),\n      biological, and clinical activity of DI-Leu16-IL2 administered to patients with CD20\n      (B-lymphocyte antigen CD20) positive Non-Hodgkin Lymphoma (NHL) that have failed standard\n      rituximab-containing therapy. Following peripheral blood B cell depletion with rituximab (if\n      needed) each patient will receive DI-Leu16-IL2 administered as a subcutaneous (SC) injection\n      for three consecutive days every three weeks (21 day cycle).  Three to six (3-6) patients\n      will be enrolled in each cohort.  Patients may receive 6 cycles of DI-Leu16-IL2\n      approximately thrice weekly for 3 weeks for a total of 18 doses."
        }, 
        "brief_title": "Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "B-cell Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Primary Endpoints\n\n             1. To determine the maximum tolerated dose (MTD) of DI-Leu16-IL2 administered      SC\n                following peripheral blood B cell depletion with rituximab in patients with B-cell\n                NHL.\n\n             2. To investigate the optimal biologic dose (OBD) of DI-Leu16-IL2 following\n                peripheral blood B cell depletion with rituximab in patients with B-cell NHL,\n                which may differ from the MTD.\n\n             3. To describe the toxicities associated with the proposed DI-Leu16-IL2 regimen.\n\n        2. Secondary Endpoints\n\n             1. To evaluate the immunogenicity as measured by the induction of\n                DI-Leu16-IL2-specific antibodies.\n\n             2. To evaluate the PK of DI-Leu16-IL2.\n\n             3. To measure the response rate at the MTD (and/or OBD) associated with the proposed\n                therapy and survival endpoints of the enrolled patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with CD20-expressing B-cell NHL that is relapsed or refractory to standard\n             therapy. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with peripheral\n             blood leukemia/lymphoma cells and high-grade lymphomas are excluded\n\n          2. Patients must have received prior rituximab-containing therapy.\n\n          3. Measurable disease. In the absence of lymphadenopathy, splenomegaly with defects or\n             measurable extra-medullary disease is acceptable.  Patients with bone marrow\n             involvement alone will not be included\n\n          4. Patients who have received a prior autologous stem cell transplant are eligible if\n             the transplant occurred > 6 months ago.\n\n          5. Patients who have received a prior allogeneic stem cell transplant are eligible if:\n\n               1. The transplant occurred > 6 months ago\n\n               2. There is no evidence of active graft vs host disease\n\n               3. Systemic immunosuppressive agents (including corticosteroids) have not been\n                  received for at least 8 weeks\n\n          6. Age \u226518 years\n\n          7. Karnofsky performance scale \u226570%\n\n          8. Life expectancy \u226512 weeks\n\n          9. Adequate baseline functions:\n\n               1. Serum creatinine \u2264 1.5 mg/dl\n\n               2. Total white blood cell count (WBC) \u2265 3000/\u00b5l, or absolute neutrophil count (ANC)\n                  \u2265 1000/\u00b5l\n\n               3. Lymphocyte count \u22650.5 x 10^3/\u00b5l\n\n               4. Platelet count \u226575,000/\u00b5l\n\n               5. Hematocrit \u2265 25% or hemoglobin \u22659 g/100 mL\n\n               6. Alanine aminotransferase (ALT) <2.5 x upper limit of normal (UNL)\n\n               7. Aspartate aminotransferase (AST) <2.5 x UNL\n\n               8. Total bilirubin (TBili) <1.5 x ULN\n\n               9. Sodium, potassium, and phosphorus within normal limits\n\n              10. Chest x-ray (CXR) or computed tomography CT within 4 weeks prior to Day 1 with\n                  no evidence of pulmonary congestion, pleural effusions, pulmonary fibrosis, or\n                  significant emphysema.  If results are questionable, patients should have\n                  additional lung function testing to exclude clinically relevant restriction or\n                  obstruction.  Patients must have a forced expiratory volume (FEV-1) and\n                  Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) of at least 65% and\n                  50% of expected, respectively.\n\n              11. Electrocardiogram (12-lead ECG) QTc \u2264 450 ms\n\n              12. Cardiac stress test (e.g., stress thallium scan, stress echocardio\u00acgraphy) with\n                  normal results if patient is suspected to have coronary artery disease.\n\n         10. Patients must use adequate birth control measures during study participation.\n             Females of childbearing potential must have a negative serum pregnancy test on the\n             days of dosing. A female of childbearing potential is a sexually mature woman who: 1)\n             has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been\n             naturally postmenopausal for at least 24 consecutive months\n\n         11. Provide written informed consent prior to any screening procedures\n\n        Exclusion Criteria:\n\n          1. Evidence of central nervous system lymphoma or lymphomatous meningitis\n\n          2. Prior treatment with IL2 within the last 5 years\n\n          3. Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous\n             infusion of rituximab\n\n          4. Pregnant or lactating female\n\n          5. An immediate need for palliative radiotherapy or systemic corticosteroid therapy\n\n          6. Known intercurrent infections (including hepatitis C virus and human immunodeficiency\n             virus or other conditions), or clinical evidence of these conditions\n\n          7. Actively infected with or chronic carriers of hepatitis B virus as demonstrated by\n             positive hepatitis B core antibody or hepatitis B surface antigen. (Patients who are\n             seropositive only, i.e. surface antibody positive [HbsAb], are permitted)\n\n          8. Other significant active infection.\n\n          9. Major surgery, chemotherapy, investigational agent, or radiation within 30 days of\n             Day 1\n\n         10. Uncontrolled hypertension (diastolic greater to or equal to 100 mmHg) or hypotension\n             (systolic less than or equal to 90 mmHg)\n\n         11. History of repeated and clinically relevant episodes of syncope or other paroxysmal,\n             ventricular, or other significant arrhythmias\n\n         12. History of medically significant ascites requiring repetitive paracentesis\n\n         13. Previous diagnosis of autoimmune disease (Exceptions: patients with autoimmune\n             thyroiditis or vitiligo may be enrolled)\n\n         14. Organ transplant recipient\n\n         15. History of prior therapy or a serious, uncontrolled medical disorder that in the\n             Investigator's opinion would impair participation in the study\n\n         16. Known hypersensitivity to Tween-80, or human immunoglobulin\n\n         17. Legal incapacity or limited legal capacity\n\n         18. Patients with bulky lymph nodes (LNs) (> 10 cm) or marked splenomegaly\n\n         19. Circulating levels of rituximab > 75.0 \u00b5g/ml"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874288", 
            "org_study_id": "AO-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "0.5 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "0.5 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1.0 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "1.0 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2.0 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "2.0 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4.0 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "4.0 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "6.0 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "6.0 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "8.0 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "8.0 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "10.0 mg/m2 DI-Leu16-IL2", 
                "description": "If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed.  Each patient will receive the same dose level assigned at the time of enrollment.  No intra- patient dose escalation will be permitted.", 
                "intervention_name": "10.0 mg/m2 DI-Leu16-IL2", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interleukin-2"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NHL", 
            "Immunocytokine", 
            "Lymphoma", 
            "Non-Hodgkin", 
            "B-cell", 
            "IL (interleukin)"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": [
            {
                "description": "Sponsor website", 
                "url": "http://www.alopexx.com"
            }, 
            {
                "description": "National Cancer Institute at the National Institute of Health", 
                "url": "http://www.cancer.gov/cancertopics/types/non-hodgkin"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "rnakamura@coh.org", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Ryotaro Nakamura, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bach0173@umn.edu", 
                    "last_name": "Veronika Bachanova, M.D.", 
                    "phone": "612-625-5469"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Veronika Bachanova, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "frederick.lansigan@hitchcock.org", 
                    "phone": "603-650-5529"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth-Hitchcock Medical Center"
                }, 
                "investigator": {
                    "last_name": "Frederick Lansigan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)", 
        "overall_contact": {
            "email": "michelle.nelken@alopexx.com", 
            "last_name": "Michelle Nelken", 
            "phone": "617-755-4149"
        }, 
        "overall_official": {
            "affiliation": "Alopexx Oncology, LLC", 
            "last_name": "Daniel Vlock, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the maximum tolerated dose of DI-Leu16-IL2 administered following peripheral blood B cell depletion with rituximab in patients with B-cell NHL.", 
            "measure": "Maximum tolerated dose of DI-Leu16-IL2", 
            "safety_issue": "Yes", 
            "time_frame": "6 month treatment period"
        }, 
        "reference": [
            {
                "PMID": "15483010", 
                "citation": "King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15;22(22):4463-73. Epub 2004 Oct 13."
            }, 
            {
                "PMID": "15076141", 
                "citation": "Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun;27(3):232-9."
            }, 
            {
                "PMID": "7522629", 
                "citation": "Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874288"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the immunogenicity as measured by the induction of DI-Leu16-IL2-specific antibodies.", 
            "measure": "Evaluate immunogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "pre-dose on Day 1 of Cycles 1-4"
        }, 
        "source": "Alopexx Oncology, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alopexx Oncology, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}